能倍乐的功效和作用
Efficacy and role of Respimat: It is a bronchodilator, suitable for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, the maintenance treatment of accompanying dyspnea and the prevention of acute exacerbations. It can improve the quality of life of COPD patients and reduce acute exacerbations of COPD.
Respimat is a long-acting, specific antimuscarinic drug commonly referred to clinically as an anticholinergic drug. By binding to muscarinic receptors on bronchial smooth muscle, Respimat inhibits the cholinergic (bronchoconstrictor) effects of acetylcholine released from parasympathetic nerve terminals. It has similar affinity for muscarinic receptor subtypes M1-M5. In the respiratory tract, Respimat competitively and reversibly inhibits M3 receptors, causing smooth muscle relaxation. This effect is dose-dependent and can last for more than 24 hours. The long effect may be due to its very slow dissociation from the M3 receptor, and its dissociation half-life is significantly longer than that of ipratropium bromide.
The focus of COPD management is to reduce symptoms and prevent acute exacerbations. Respimat can significantly improve patients' lung function, reduce symptoms of COPD, improve quality of life, and effectively reduce the incidence of acute exacerbations. In addition, its original soft mist inhalation device realizes active spraying, which is easy for patients to inhale and ensures efficient lung deposition, which is conducive to ensuring the clinical efficacy of the drug. The approval of Respimat provides a new option for COPD patients and has important clinical value and social significance.
Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.
Recommended related articles:
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)